PF-05280014
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for PF-05280014, covering 2012-12-18 to 2018-01-23. Get the full timeline:
Most recent: Clinical Trial Update: A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) [Phase 3]